Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Arzneimittel-Forschung

• Publication date

  1992-07-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 1418054
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Memantine is highly potent in protecting cortical cultures against excitotoxic cell death evoked by glutamate and N-methyl-D-aspartate.

  1991cited by this paper
• Neuroprotective effect of memantine demonstrated in vivo and in vitro.

  1990cited by this paper
• Consensus Conference on the Methodology of Clinical Trials of "Nootropics", Munich, June 1989

  1990cited by this paper
• Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex.

  1989cited by this paper
• Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels.

  1989cited by this paper
• Excitatory amino acid receptors in the vertebrate central nervous system.

  1989cited by this paper
• Treatment of Impaired Cerebral Function in Psychogeriatric Patients with Memantine - Results of a Phase II Double-Blind Study

  1988cited by this paper
• Glutamate transmission and toxicity in Alzheimer's disease.

  1988cited by this paper
• Acute dendrotoxic changes in the hippocampus of kainate treated rats.

  1979cited by this paper
• Cerebral blood flow in dementia.

  1975cited by this paper

• Integrating axis quantitative trait loci looks beyond cell types and offers insights into brain-related traits

  2025cites this paper
• Memantine for dementia.

  2019cites this paper
• Receptor Targets in Alzheimer’s Disease Drug Discovery

  2017cites this paper
• Memantine in the Treatment of Alzheimer’s Disease: 20 Years of Clinical Use

  2017cites this paper
• [Memantine in treatment of Alzheimer's disease: 20 years of clinical use].

  2016cites this paper
• Vascular cognitive impairment, a cardiovascular complication.

  2016cites this paper
• Plant derived alkaloids in major neurodegenerative diseases: from animal models to clinical trials

  2015cites this paper
• Critical Assessment of Implantable Drug Delivery Devices in Glaucoma Management

  2013cites this paper
• AVALIAÇÃO DA ASSOCIAÇÃO ENTRE O EFEITO NEUROPROTETOR E ANTIDEPRESSIVO DA ATORVASTATINA EM CAMUNDONGOS

  2012cites this paper
• A Validated Time of Flight Mass Spectrometry for Quantitative Determination of Amantadine Hydrochloride and Memantine

  2012cites this paper
• Effect of memantine in aging : the impact of hippocampal dependent memory

  2011cites this paper
• Serotonin transporter polymorphism as a predictor for escitalopram treatment of major depressive disorder comorbid with alcohol dependence.

  2011cites this paper
• Effect of Memantine in Aging: the Impact on Hippocampal Dependent Memory.

  2011cites this paper
• A Validated Stability-indicating Reverse Phase HPLC Assay Method for the Determination of Memantine Hydrochloride Drug Substance with UV-Detection Using Precolumn Derivatization Technique

  2010cites this paper
• Toole's Cerebrovascular Disorders: Hematological Disorders and Hypercoagulable States

  2010cites this paper
• A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors

  2010cites this paper
• Age at onset of first depressive episode as a predictor for escitalopram treatment of major depression comorbid with alcohol dependence.

  2009cites this paper
• Neuroprotective and symptomatological action of memantine relevant for alzheimer’s disease — a unified glutamatergic hypothesis on the mechanism of action

  2009cites this paper
• The neuroprotectant properties of glutamate antagonists and antiglutamatergic drugs

  2009cites this paper
• Antinociceptive effects of chronic administration of uncompetitive NMDA receptor antagonists in a rat model of diabetic neuropathic pain.

  2009cites this paper
• Therapeutic opportunities in Alzheimer disease: Current concepts

  2009cites this paper
• Memantine for the Treatment of Alzheimer’s Disease

  2008cites this paper
• Treatment of patients comorbid with alcohol dependence and major depressive disorder with memantine and escitalopram - outcome and predictors

  2008cites this paper
• Memantine: potential and demonstrated effects of a new drug

  2008cites this paper
• NMDA receptors in clinical neurology: excitatory times ahead.

  2008cites this paper
• Inflammation and aging: can endocannabinoids help?

  2008cites this paper
• Substance Abuse Treatment, Prevention, and Policy Treatment of Alcohol Dependence in Patients with Co-morbid Major Depressive Disorder – Predictors for the Outcomes with Memantine and Escitalopram Medication

  2008cites this paper
• Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence.

  2008cites this paper
• New treatment options for vascular dementia

  2007cites this paper
• Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline

  2007cites this paper
• Effect of memantine on neuroretinal function and retinal vascular changes of streptozotocin-induced diabetic rats.

  2007cites this paper
• Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees?

  2007cites this paper
• The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease.

  2006cites this paper
• Memantine for dementia.

  2006cites this paper
• [The action of memantine on the cognitive disorders of patients with dementia: reflections following two years' experience in Spain].

  2006cites this paper
• Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine.

  2006cites this paper
• Coadministration of Memantine with Acetylcholinesterase Inhibitors

  2006cites this paper
• Mechanisms of Otoprotection

  2006cites this paper
• Beneficios clínicos de la memantina en las alteraciones de la capacidad para realizar actividades de la vida diaria en pacientes con enfermedad de Alzheimer. Revisión sistemática de la bibliografía médica

  2006cites this paper
• Vascular dementia: prevention and treatment

  2006cites this paper
• Alzheimer Disease and Its Management: A Review

  2006cites this paper
• Treatment Effect Size of Memantine Therapy in Alzheimer Disease and Vascular Dementia

  2006cites this paper
• Apoptosis: A Friend Or Foe?

  2005cites this paper
• Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model

  2005cites this paper
• Acupuncture improved cognitive impairment caused by multi-infarct dementia in rats.

  2005cites this paper
• Cholinergic and glutamatergic drugs in Alzheimer’s disease therapy

  2005cites this paper
• Meta‐analysis of memantine: Summary and commentary on the Cochrane Collaboration's systematic review

  2005cites this paper
• Memantine destinee au traitement de la maladie d'alzheimer legere et legere a moderee

  2005cites this paper
• Guidelines for the Treatment of Alzheimer’s Disease from the Italian Association of Psychogeriatrics

  2005cites this paper
• Memantine for dementia.

  2005cites this paper
• Therapeutic opportunities in Alzheimer disease: one for all or all for one?

  2005cites this paper
• Beyond Monoamines: Glutamatergic Function in Mood Disorders

  2005cites this paper
• GABA and glutamate systems as therapeutic targets in depression and mood disorders

  2005cites this paper
• [Efficacy of memantine in the treatment of Alzheimer's disease].

  2005cites this paper
• Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.

  2005cites this paper
• Pharmacological Treatment of Vascular Dementia

  2005cites this paper
• Memantine does not influence AChE inhibition in rat brain by donepezil or rivastigmine but does with DFP and metrifonate in in vivo studies

  2005cites this paper
• Memantine: Targeting glutamate excitotoxicity in Alzheimer's disease and other dementias

  2005cites this paper
• Medicamenteuze behandeling van de ziekte van Alzheimer. De klinische praktijk in Nederland

  2005cites this paper
• Identification of Genes Regulated by Memantine and MK-801 in Adult Rat Brain by cDNA Microarray Analysis

  2004cites this paper
• Memantine

  2004cites this paper
• Vascular cognitive impairment and dementia

  2004cites this paper
• [Mémantine (Ebixa): a new therapeutic strategy for the treatment of moderate to severe forms of Alzheimer's disease].

  2004cites this paper
• Mémantine (Ebixa®) : une nouvelle stratégie thérapeutique dans le traitement des formes modérément sévères à sévères de la maladie d’Alzheimer

  2004cites this paper
• Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures.

  2004cites this paper
• Memantine : A New Treatment Option for Patients with Moderate-to-Severe Alzheimer ’ s Disease

  2004cites this paper
• General Remarks on the Bridging Between Basic Research and Clinics

  2004cites this paper
• Memantine hydrochloride: pharmacological and clinical profile.

  2004cites this paper
• Neuronal Apoptosis in Neurodegenerative Diseases: From Basic Research to Clinical Application

  2004cites this paper
• Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures.

  2004cites this paper
• Memantine: An antiglutamatergic option for dementia

  2004cites this paper
• Memantine for the treatment of dementia.

  2003cites this paper
• Glutamate and depression: clinical and preclinical studies.

  2003cites this paper
• Memantine: update on the current evidence

  2003cites this paper
• Memantine in Vascular Dementia

  2003cites this paper
• Antioxidant treatment in alzheimer’s disease

  2003cites this paper
• Clinical Studies Implementing Glutamate Neurotransmission in Mood Disorders

  2003cites this paper
• Evaluation of memantine for the treatment of Alzheimer’s disease

  2003cites this paper
• Pharmacologic Manipulation of the Labyrinth with Novel and Traditional Agents Delivered to the Inner Ear

  2003cites this paper
• ▼Memantine for dementia?

  2003cites this paper
• Profile of Ketamine, CPP, Dextromethorphan, and Memantine

  2003cites this paper
• Memantine

  2003cites this paper
• [Use of memantine in progressive glaucoma. Case report].

  2002cites this paper
• Diagnosis and management of vascular cognitive impairment and dementia.

  2002cites this paper
• Vascular cognitive impairment.

  2002cites this paper
• Neuroprotective Effect of Memantine in Different Retinal Injury Models in Rats

  2002cites this paper
• Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular Dementia: A Randomized, Placebo-Controlled Trial (MMM 300)

  2002cites this paper
• Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments

  2002cites this paper
• Einsatz von Memantine bei Glaucoma fere absolutum

  2002cites this paper
• Glutamate receptors as a target for Alzheimer's disease--are clinical results supporting the hope?

  2002cites this paper
• The neuroprotective agent memantine induces brain-derived neurotrophic factor and trkB receptor expression in rat brain.

  2001cites this paper
• Glutamate‐induced excitation and sensitization of nociceptors in rat glabrous skin

  2001cites this paper
• CME Practice parameter : Management of dementia ( an evidence-based review ) Report of the Quality Standards Subcommittee of the American Academy of Neurology

  2001cites this paper
• Efficacy and safety of memantine, an NMDA-type open-channel blocker, for reduction of retinal injury associated with experimental glaucoma in rat and monkey.

  2001cites this paper
• Practice parameter: Management of dementia (an evidence-based review)

  2001cites this paper
• Vascular Cognitive Impairment

  2001cites this paper
• Targeting the N-methyl-D-aspartate receptor for chronic pain management. Preclinical animal studies, recent clinical experience and future research directions.

  2000cites this paper
• Neue Aspekte in der antidementiven Pharmakotherapie der Alzheimer-Erkrankung

  2000cites this paper
• Memantine (a N-Methyl-d-Aspartate Receptor Antagonist) in the Treatment of Neuropathic Pain After Amputation or Surgery: A Randomized, Double-Blinded, Cross-Over Study

  2000cites this paper
• A Prospective PMS Study to Validate the Sensitivity for Change of the D-Scale in Advanced Stages of Dementia Using the NMDA-Antagonist Memantine

  2000cites this paper